(Q34568721)

3 August 2017

1 reference

title

GM-CSF-based cellular vaccines: a review of the clinical experience (English)

1 reference

3 August 2017

Ivan Borrello

1

1 reference

3 August 2017

Drew Pardoll

series ordinal

2

1 reference

3 August 2017

publication date

1 April 2002

1 reference

Cytokine and Growth Factor Reviews

3 August 2017

published in

1 reference

3 August 2017

volume

13

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

185-193

1 reference

Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Multiple tumour-specific antigens expressed on a single tumour cell

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Role of Fas ligand expression in promoting escape from immune rejection in a spontaneous tumor model

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

T-cell tolerance by clonal anergy in transgenic mice with nonlymphoid expression of MHC class II I–E

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Flt3 ligand induces tumor regression and antitumor immune responses in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

The Yin and Yang of T cell costimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Human tumor antigens recognized by T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

1 reference

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

1 reference

7 January 2021

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Tolerance, danger, and the extended family

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Paracrine cytokine adjuvants in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Demonstration of a rational strategy for human prostate cancer gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Peptide-induced antiviral protection by cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Combination of CD80 and granulocyte-macrophage colony-stimulating factor coexpression by a leukemia cell vaccine: preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte respons

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

Enhanced adjuvant effect of granulocyte-macrophage colony-stimulating factor plus interleukin-12 compared with either alone in vaccine-induced tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900034-X

7 January 2021

10.1016/S1359-6101(01)00034-X

Identifiers

DOI

1 reference

3 August 2017

1 reference